Found: 22
Select item for more details and to access through your institution.
In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
- Published in:
- 2017
- By:
- Publication type:
- journal article
T-2307, a novel arylamidine, is transported into Candida albicans by a high-affinity spermine and spermidine carrier regulated by Agp2.
- Published in:
- 2016
- By:
- Publication type:
- journal article
The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Association of CRP levels with ARMS2 and CFH variants in age-related macular degeneration.
- Published in:
- International Ophthalmology, 2020, v. 40, n. 10, p. 2735, doi. 10.1007/s10792-020-01460-y
- By:
- Publication type:
- Article
Influence of inoculum size of <it>Staphylococcus aureus</it> and <it>Pseudomonas aeruginosa</it> on <it>in vitro</it> activities and <it>in vivo</it> efficacy of fluoroquinolones and carbapenems.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2005, v. 56, n. 1, p. 91, doi. 10.1093/jac/dki163
- By:
- Publication type:
- Article
Distinct characteristics of central serous chorioretinopathy according to gender.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-14777-8
- By:
- Publication type:
- Article
Association of Polyp Regression after Loading Phase with 12-Month Outcomes of Eyes with Polypoidal Choroidal Vasculopathy.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 6, p. 687, doi. 10.3390/ph17060687
- By:
- Publication type:
- Article
A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 4, p. 562, doi. 10.3390/ph16040562
- By:
- Publication type:
- Article
Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration.
- Published in:
- Pharmaceuticals (14248247), 2020, v. 13, n. 9, p. 257, doi. 10.3390/ph13090257
- By:
- Publication type:
- Article
Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 5, p. 1098, doi. 10.3390/jcm10051098
- By:
- Publication type:
- Article
Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 8, p. 2459, doi. 10.3390/jcm9082459
- By:
- Publication type:
- Article
Characteristics of intermediate age-related macular degeneration with hyperreflective foci.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-23380-w
- By:
- Publication type:
- Article
Repeated Measurements Are Necessary for Evaluating Accurate Diurnal Rhythm Using a Self-Intraocular Pressure Measurement Device.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 7, p. 2460, doi. 10.3390/jcm12072460
- By:
- Publication type:
- Article
Mid-Term Results of Ab Interno Trabeculectomy among Japanese Glaucoma Patients.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 6, p. 2332, doi. 10.3390/jcm12062332
- By:
- Publication type:
- Article
Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-64301-z
- By:
- Publication type:
- Article
Clinical and genetic characteristics of pachydrusen in patients with exudative age-related macular degeneration.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-48494-6
- By:
- Publication type:
- Article
Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results.
- Published in:
- PLoS ONE, 2020, v. 15, n. 8, p. 1, doi. 10.1371/journal.pone.0237330
- By:
- Publication type:
- Article
Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy.
- Published in:
- PLoS ONE, 2020, v. 15, n. 2, p. 1, doi. 10.1371/journal.pone.0229231
- By:
- Publication type:
- Article
Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy.
- Published in:
- Biomedicines, 2021, v. 9, n. 9, p. 1164, doi. 10.3390/biomedicines9091164
- By:
- Publication type:
- Article
Bactericidal activity of garenoxacin against in vitro biofilm formed by nontypeable Haemophilus influenzae.
- Published in:
- Journal of Infection & Chemotherapy (Springer Science & Business Media B.V.), 2013, v. 19, n. 3, p. 441, doi. 10.1007/s10156-012-0502-8
- By:
- Publication type:
- Article
Comparison of one-year outcomes between as-needed brolucizumab and aflibercept for polypoidal choroidal vasculopathy.
- Published in:
- Japanese Journal of Ophthalmology, 2023, v. 67, n. 4, p. 402, doi. 10.1007/s10384-023-00999-4
- By:
- Publication type:
- Article